<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5DC8742C-F283-44E9-9393-25DE98BDE551"><gtr:id>5DC8742C-F283-44E9-9393-25DE98BDE551</gtr:id><gtr:firstName>Geraldine</gtr:firstName><gtr:surname>Taylor</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FI%2F00001325"><gtr:id>E8FC665A-96E2-4800-9EB2-B84BF3CC60FA</gtr:id><gtr:title>Evaluation of mucosal vaccination with live, attenuated mutant bovine respiratory syncytial viruses</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/I/00001325</gtr:grantReference><gtr:abstractText>The principal scientific objectives are to: 1. Determine the effects of mucosal vaccination with live, attenuated mutant BRSV on the magnitude and duration of BRSV-specific CD4+ and CD8+ T-cell memory; 2 Determine the effects of mucosal vaccination with live, attenuated mutant BRSV on the magnitude and duration of BRSV-specific antibodies in serum and nasal secretions; 3. Determine the duration of protective immunity induced by mucosal vaccination with live, attenuated mutant BRSV; 4. Investigate the interaction of Mycoplasma bovis with bovine airway epithelial cells and macrophages.</gtr:abstractText><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2007-04-01</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>84856</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>239067</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Horizon 2020</gtr:description><gtr:end>2019-02-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>633184</gtr:fundingRef><gtr:id>0CB71C31-98FC-4B6B-91FC-EF9B8C4A632E</gtr:id><gtr:outcomeId>56dec75eb72275.82206227</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>A mutant bovine respiratory syncytial virus lacking the SH gene, which was shown to be attenuated in calves and induce protection against challenge with virulent virus has been licensed to a Veterinary Pharmaceutical company with a view to further evaluation as a commercial vaccine.</gtr:description><gtr:firstYearOfImpact>2010</gtr:firstYearOfImpact><gtr:id>7B0D7D70-A81A-40C4-A1C9-2F1A13E98C8F</gtr:id><gtr:impactTypes/><gtr:outcomeId>545cb36c996a60.36669268</gtr:outcomeId><gtr:sector>Agriculture, Food and Drink</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>The immunogenicity and protective efficacy of mucosal vaccination of calves with six attenuated recombinant bovine respiratory syncytial virus (BRSV) against BRSV challenge were compared, 6 months after vaccination. These studies demonstrated that intranasal and intratracheal inoculation of 2 to 4 week-old, BRSV-seronegative, calves with rBRSV lacking the SH protein (rBRSV?SH) provided complete protection against subsequent challenge with virulent BRSV, whereas protection induced by the other 5 mutant rBRSV was incomplete. Furthermore, analysis of the antibody and T-cell responses induced by the various mutant BRSV suggested that BRSV-specific IgA in nasal secretions at the time of challenge correlated with protection against replication of the challenge virus in the nasopharynx. 
Preliminary studies analysing the interaction of the mutant rBRSV with bovine alveolar macrophages and monocytes suggested that the induction of certain pro-inflammatory cytokines by rBRSV?SH may play a role in the development of the protective adaptive immune response. However, further studies are needed to investigate this hypothesis.</gtr:description><gtr:exploitationPathways>Further studies are needed to determine the protective efficacy of rBRSV?SH when administered by the intranasal route alone and the effects of maternally-derived BRSV-specific antibodies on induction of protective immunity.</gtr:exploitationPathways><gtr:id>21FB4708-310C-439D-ACFE-38FF278057A2</gtr:id><gtr:outcomeId>545cb2cf4a3f06.39996349</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6A0AFB4E-08E8-4723-BFE0-90EA8A2A02AE</gtr:id><gtr:title>Recombinant bovine respiratory syncytial virus with deletion of the SH gene induces increased apoptosis and pro-inflammatory cytokines in vitro, and is attenuated and induces protective immunity in calves.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb166f172d6376a3795a3a2d84a54351"><gtr:id>bb166f172d6376a3795a3a2d84a54351</gtr:id><gtr:otherNames>Taylor G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>545c9e1321fd41.50172706</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0547D20B-1AB7-4FB0-A342-FC2A03FE28E6</gtr:id><gtr:title>Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3df7d9c06e28d0a0323b53f564b4a72e"><gtr:id>3df7d9c06e28d0a0323b53f564b4a72e</gtr:id><gtr:otherNames>Blod?rn K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>545cae77ca79d0.87430639</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/I/00001325</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>